Beyfortus (Nirsevimab) – RSV Prevention for Babies: Considerations for Pediatric Practice Managers and Leaders

Pediatric Medical Billing, Pediatric Office Management, Pediatric Vaccinations

Background The RSV prevention, Beyfortus (nirsevimab) which is a monoclonal antibody, was approved by the FDA on July 17, 2023.  The CDC and ACIP provided recommendations which were published in the MMWR on August 25, 2023. The FDA accelerated approval of Beyfortus since the RSV prevention was categorized as “Breakthrough Therapy Designation”.  Note that Beyfortus…